Could a new shot shield babies from deadly meningitis?
NCT ID NCT07505823
First seen Apr 05, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis in infants aged 6 to 11 months. About 1,040 healthy babies will receive either the experimental vaccine or a licensed comparator. Researchers will check immune responses and safety after two doses and a booster at 18 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDEMIC MENINGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Group ACYW135 Meningococcal Conjugate Vaccine
What this could lead to
If successful, this could provide a safe and effective vaccine option to protect infants against four types of meningococcal bacteria that cause meningitis.
What could go wrong
This is an early-stage Phase 3 trial, and the vaccine may not prove as effective or safe as the existing licensed vaccine. Results are based on immune markers, not actual disease prevention.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.